ERS Genomics signs CRISPR patent deal on industrial applications
ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
The companies announced the non-exclusive deal today, October 16, saying that it provides Syngulon with worldwide access to ERS’s CRISPR/Cas9 IP for use in combination with Syngulon’s patent rights.
Belgium-based Syngulon develops original genetic technologies using bacteriocins, otherwise known as anti-microbial peptides.
“Genome-editing has many applications beyond drug discovery and development, and making the CRISPR/Cas9 patents available to synthetic biology startups such as Syngulon is a growing and important part of our business,” said Eric Rhodes, CEO of ERS, based in Dublin.
Philippe Gabant, co-founder of Syngulon, added that by combining modern genetics with synthetic biology, Syngulon is developing its collection of bacteriocins to fight contaminants in different industrial applications.
“Syngulon out-licenses its patented technologies on a non-exclusive basis and will be able to sub-license ERS’s CRISPR/Cas9 patents as part of a joint licensing agreement thus enabling its licensees to benefit from the use of CRISPR/Cas9 genome-editing in implementing Syngulon’s technologies using bacteriocins,” he added.
Financial details of the agreement were not disclosed.
News of the deal comes just a month after ERS signed one CRISPR licensing agreement with Thermo Fisher Scientific, covering products, tools and services for research, and expanded another—which is directed to the supply of CRISPR-modified cell lines—with Oxford Genetics. Both agreements were also non-exclusive.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk